Brett A.  Wall net worth and biography

Brett Wall Biography and Net Worth

EVP of Medtronic
Brett Wall is Executive Vice President and President of Medtronic’s Neuroscience Portfolio that is comprised of five unique Operating Units—Neuromodulation, Cranial & Spinal Technologies, Neurovascular, Pelvic Health and Ear, Nose and Throat. Together, these Operating Units generate over $8B in annual revenue and employ approximately 15,000 employees worldwide. Brett also serves as a member of the company’s Executive Committee.

Previously, he was Senior Vice President of the legacy Brain Therapies division which is part of the Neuroscience portfolio.

Brett also serves as the Executive Sponsor of the Medtronic African Descent Network — an internal national resource group that focuses on recruitment, engagement, retention and development for employees of African descent.

Prior to the Medtronic acquisition of Covidien, Brett served as Covidien President, Neurovascular and International, where he managed all commercial activities and functions of the business resulting in a doubling of revenue during his tenure.

He also served as Senior Vice President and President, Neurovascular; and Senior Vice President and President, International, at ev3, Inc. Prior to the ev3 merger with Micro Therapeutics, Brett held the positions of Micro Therapeutic Vice President, Marketing, for the Neurovascular and Peripheral Vascular divisions.

Brett’s career journey also included work at Boston Scientific as the Director of Marketing, Cardiovascular, Asia Pacific; and Marketing Manager, Japan, where he was responsible for the Interventional Cardiology product lines within the Asia-Pacific region. In addition, he held positions of increasing responsibility at C.R. Bard, where he was responsible for marketing the company’s suite of urological products.

Brett currently serves on the board executive committee for OCTANe, a group that promotes technical growth and expertise in the greater Orange County, California area. He also is a member of the CEO Roundtable at the University of California, Irvine. Previously, Brett served as Chairman of the Heart and Stroke Ball for the American Heart Association, Orange County Chapter.

Brett earned his bachelor’s degree in Comprehensive Business Administration with an emphasis in Marketing from the University of Nebraska at Kearney. He is a resident of Southern California.

What is Brett A. Wall's net worth?

The estimated net worth of Brett A. Wall is at least $2.48 million as of December 19th, 2023. Mr. Wall owns 28,910 shares of Medtronic stock worth more than $2,483,947 as of May 18th. This net worth estimate does not reflect any other investments that Mr. Wall may own. Learn More about Brett A. Wall's net worth.

How do I contact Brett A. Wall?

The corporate mailing address for Mr. Wall and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Brett A. Wall's contact information.

Has Brett A. Wall been buying or selling shares of Medtronic?

Brett A. Wall has not been actively trading shares of Medtronic during the last quarter. Most recently, Brett A. Wall sold 4,997 shares of the business's stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $82.17, for a transaction totalling $410,603.49. Following the completion of the sale, the executive vice president now directly owns 28,910 shares of the company's stock, valued at $2,375,534.70. Learn More on Brett A. Wall's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 8 times. They sold a total of 56,412 shares worth more than $4,783,509.24. The most recent insider tranaction occured on April, 8th when EVP Michael Marinaro sold 854 shares worth more than $71,001.56. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 4/8/2024.

Brett A. Wall Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2023Sell4,997$82.17$410,603.4928,910View SEC Filing Icon  
8/14/2023Sell1,000$83.38$83,380.0033,573View SEC Filing Icon  
7/14/2023Sell2,000$87.97$175,940.0023,948View SEC Filing Icon  
6/21/2021Sell115$123.50$14,202.5022,655View SEC Filing Icon  
6/1/2021Sell2,473$128.07$316,717.11View SEC Filing Icon  
See Full Table

Brett A. Wall Buying and Selling Activity at Medtronic

This chart shows Brett A Wall's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $85.92
Low: $85.10
High: $86.17

50 Day Range

MA: $82.91
Low: $79.08
High: $87.15

2 Week Range

Now: $85.92
Low: $68.84
High: $91.00

Volume

8,236,275 shs

Average Volume

5,266,071 shs

Market Capitalization

$114.09 billion

P/E Ratio

27.36

Dividend Yield

3.22%

Beta

0.78